Metformin Therapy for Improving Uterine Environment

Introduction to Metformin Therapy

The American College of Obstetricians and Gynecologists confirms that metformin should not be expected to improve fertility in the immediate cycle 1
Metformin may restore ovulation unpredictably, potentially leading to unplanned pregnancy before optimal metabolic control is achieved, hence contraception counseling is mandatory 1
Children exposed to metformin in utero demonstrate higher BMI, increased waist circumference, and increased obesity risk at ages 4-10 years 1

Clomiphene citrate or letrozole are first-line if pregnancy is desired urgently, as these achieve significantly higher pregnancy rates than metformin alone 1
Clomiphene citrate achieves an 80% ovulation rate and 50% conception rate as first-line therapy 2
The American College of Obstetricians and Gynecologists confirms that metformin is not first-line therapy for ovulation induction 1

Start metformin at therapeutic doses of 1.5-2g daily for long-term metabolic and reproductive benefits 3, 1
Typical effective dosing is 1000 mg twice daily for 12 weeks minimum 4, 3
Use barrier methods or hormonal contraception for at least 3-6 months while metformin achieves therapeutic effects 1
Approximately 60% of PCOS women have insulin resistance regardless of BMI, and restoration of ovulation can occur unpredictably 2

Even 5% weight loss enhances metformin's metabolic and reproductive effects 1, 2
This synergistic approach is supported by the American Academy of Family Physicians 2
Insulin resistance drives hyperandrogenism and anovulation through increased ovarian androgen production 3, 2
Metformin decreases hepatic gluconeogenesis and increases peripheral glucose uptake, which reduces insulin levels and subsequently decreases ovarian androgen production 3, 2

Renal impairment if eGFR <30 mL/min/1.73m² is an absolute contraindication for metformin therapy 1, 2
The National Kidney Foundation recommends assessing renal function before initiating metformin 2
The American Association for the Study of Liver Diseases recommends screening for hepatic disease before initiation 2

Liraglutide 1.8 mg daily or semaglutide are emerging alternatives for PCOS patients with inadequate response to metformin monotherapy 2
GLP-1 RAs combined with metformin may provide additional benefits for weight reduction and metabolic parameters 3
Metformin combined with clomiphene citrate is more effective than either alone for clomiphene-resistant cases 3